Casodex/Zoladex Biomarkers in Localised Prostate Cancer

Phase 4

Completed

• Conditions: Prostate Cancer

• Registration Number: NCT00293696
• Lead Sponsor: Tampere University

Brief Summary

To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones

Detailed Description

Not available

Study Timeline

• Study Start: 2004-10
• Study First Submitted: 2006-02-16
• Study First Submitted QC: 2006-02-16
• Study First Posted: 2006-02-17
• Study Completion: 2006-11
• Status Verified: 2007-05
• Last Update Submitted: 2007-05-07
• Last Update Posted: 2007-05-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

1. Histologically confirmed localised prostate biopsy specimen that contains sufficient tumour for evaluation of cell proliferation and apoptosis markers
2. Patients who are scheduled for radical prostatectomy with curative intents

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Gleason score
Proliferation by Ki67,
apoptosis marker (TUNEL assay),

Secondary Outcome Measures

Name	Time	Method
biomarkers of apoptotic pathway,
expression of known androgen-regulated genes,
(novel) genomic transcripts

Trial Locations

Locations (1)

TUCH; 🇫🇮 Tampere, Finland